ALNY Q1 2023 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$319M+49.7% YoY

Gross Profit

$264M82.8% margin

Operating Income

-$150M-46.9% margin

Net Income

-$174M-54.5% margin

EPS (Diluted)

$-1.40

QoQ Revenue Growth

-4.7%

Cash Flow

Operating Cash Flow

-$166M

Free Cash Flow

-$180M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$3.7B

Stockholders' Equity

-$259M

Cash & Equivalents

$672M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$319M	$213M	+49.7%
Gross Profit	$264M	$178M	+48.9%
Operating Income	-$150M	-$147M	-2.1%
Net Income	-$174M	-$240M	+27.6%

Revenue Segments

Product

$276M98%

Royalty

$7M2%

Geographic Segments

Europe

$13M55%

UNITED STATES

$9M37%

Non-US Or Europe

$2M7%